Skip to content

Neurological Features During COVID19

Description of neurolOgical Involvement Observed During SARS COV2 Infection

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04460599
Acronym
NeuroSARS
Enrollment
30
Registered
2020-07-07
Start date
2020-03-08
Completion date
2020-09-30
Last updated
2020-07-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Encephalitis

Keywords

Cranial nerves, brainstem, dysautonomia

Brief summary

Description of the neurological impairment: clinico-radiological and electrophysilogical correlations

Detailed description

Describe short and long term clinical radiological and electrophysilogical presentations of neurological damage central and peripheral SARS COV2 infection Describe the association between neurological, respiratory and dysautonomic Determine the prognosis of neurological damages to short and long term.

Interventions

OTHERObservation

Observation of recorded neurological signs

Sponsors

Centre d'Investigation Clinique et Technologique 805
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum

Inclusion criteria

* PCR SARS COV2 positive or CT Scan * Central neurological signs such as confusion, epilepsy, abnormal movement, pyramidal signs, motor or sensory deficit, involvement of cranial pairs (such as anomie or ageusia) or peripheral. * Dysautonomic signs such as hypotension or hypertension, bradycardia or tachycardia, hypothermia, SIADH not explained by therapy or a pathology other than SARS COV 2 infection

Exclusion criteria

* Contraindication to performing an MRI scan * Minor * Pregnant woman * No follow-up possible at 6 months

Design outcomes

Primary

MeasureTime frameDescription
Primary6 monthsincidence of objective neurological damage

Secondary

MeasureTime frameDescription
Secondary6 monthsincidence of clinical neurological damage incidence of radiological neurological damage incidence of neurophysiological neurological damage

Countries

France

Contacts

Primary ContactDavid Orlikowski, MD PhD
david.orlikowski@aphp.fr0147107777
Backup ContactIsabelle Bossard

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026